The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with evidence of improvements in symptoms and exercise capacity among people with nonobstructive hypertrophic cardiomyopathy (HCM), according to results of a 12-week phase 2 trial presented at the American College of Cardiology's Annual Scientific Session.
Phase 2 trial shows early signs that the investigational drug could relieve symptoms and improve exercise capacity in HCM patients with no other evidence-based treatment options available
Ninerafaxstat well-tolerated and safe for nonobstructive hypertrophic cardiomyopathy medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
New research shows that taking more steps 1,000 more per day is possibly tied to improved overall health for people who are living with heart failure. Those who increased steps from 1,000 to 2,000 each day saw significant improvements in physical limitation scores compared to people who didn't increase their steps.